Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 6/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | TDO2 | P48775 | 2/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CDC25A | P30304 | 2/20 | 0.40 |
| ▸ | CDC25B | P30305 | 2/20 | 0.40 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31037045 | 1.00 | HIF1A (0.54) | HIF1ARAB9ANPC1PAX8CYP1A2 | |
| SCHEMBL25975640 | 0.91 | HIF1A (0.49) | HIF1ARAB9ANPC1PAX8CYP1A2 | |
| SCHEMBL22733090 | 0.89 | IDO1 (0.47) | HIF1ARAB9ANPC1PAX8CYP1A2 | |
| SCHEMBL31037046 | 0.89 | IDO1 (0.47) | HIF1ARAB9ANPC1PAX8CYP1A2 | |
| SCHEMBL31037072 | 0.89 | HIF1A (0.61) | HIF1ARAB9ANPC1PAX8CYP1A2 | |
| SCHEMBL22733280 | 0.89 | HIF1A (0.61) | HIF1ARAB9ANPC1PAX8CYP1A2 | |
| SCHEMBL22733233 | 0.86 | HIF1A (0.51) | HIF1ARAB9ANPC1PAX8CYP1A2 | |
| SCHEMBL31037031 | 0.86 | HIF1A (0.51) | HIF1ARAB9ANPC1PAX8CYP1A2 | |
| SCHEMBL22733034 | 0.86 | NPC1 (0.43) | HIF1ARAB9ANPC1PAX8CYP1A2 | |
| SCHEMBL22733024 | 0.86 | HIF1A (0.51) | HIF1ARAB9ANPC1PAX8CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113454068-A | Benzoindazolone compounds and intermediates thereof | LMITO药业株式会社 | 2021-09-28 | — | — | CN | claimed |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| CN-113454068-A | Benzoindazolone compounds and intermediates thereof | LMITO药业株式会社 | 2021-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | PDCD1, CD274, PDCD10 | HIF1A 3197/4885RAB9A 1969/4885NPC1 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.